Immix Biopharma, Inc. (IMMX) Dividend History

Immix Biopharma, Inc. (IMMX) is a biotechnology company focused on developing and commercializing innovative therapies in the field of immuno-oncology. The company's primary goal is to advance treatments that enhance the immune system's ability to target and eliminate cancer cells, with a particular emphasis on therapies that can improve patient outcomes in oncology.

11400 West Olympic Blvd., Los Angeles, CA, 90064
Phone: (888) 958-1084
Website: https://www.immixbio.com

Dividend History

Immix Biopharma, Inc. currently does not pay dividends

Company News

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Immix Biopharma's CAR-T cell therapy NXC-201 demonstrated positive clinical results in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate and a favorable safety profile.

GlobeNewswire Inc.
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Immix Biopharma's subsidiary Nexcella has received an $8 million grant from the California Institute for Regenerative Medicine to support the clinical development of its CAR-T therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.

GlobeNewswire Inc.
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 - GlobeNewswire

Immix Biopharma has dosed the first patient in its U.S. NEXICART-2 trial evaluating NXC-201, a BCMA-targeted CAR-T therapy, for relapsed/refractory AL Amyloidosis. The trial builds on positive data from the initial ex-U.S. NEXICART-1 study, which showed a 92% overall response rate.

GlobeNewswire Inc.
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum.

GlobeNewswire Inc.
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1:

GlobeNewswire Inc.

Dividend data last updated 06/08/2025 00:04:34 UTC